Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
NeoGenomics Laboratories logo — Answers are in our DNA™

NeoGenomics Laboratories

Answers are in our DNA™

Founded 2002 United States Fort Myers, United States 1770 employees IPO Total: $750.90M Biotechnology, Health Care +1

General Information

Company Name NeoGenomics Laboratories
Founded Year 2002
Location United States Fort Myers, United States +1
Founders / Decision Makers
Kathryn B. McKenzie — Chief Financial Officer Steven A. Ross — Vice President, Chief Information Officer Lynn A. Tetrault — Chair of the Board Lawrence M. Weiss — Chief Medical Officer Jennifer M. Balliet — Chief Culture Officer
Employees 1770
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage IPO
Social

Get notified when NeoGenomics Laboratories moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

NeoGenomics Laboratories recently launched RaDaR® ST, a new product aimed at streamlining therapeutic response monitoring and delivering actionable insights for personalized cancer treatment. This product expansion, coupled with their planned exhibitor presence at the 2026 ASCO® Annual Meeting, highlights a strategic focus on enhancing their precision oncology portfolio and maintaining strong industry visibility for their advanced diagnostic solutions.

Signal Types
Product Launch Market Presence
Strategic Labels
Product Expansion Precision Oncology Enhancement Market Engagement
Next Move: Hiring
·
Impact: 8/10
·
Ideal For: Growth Equity Investors — Precision Oncology

About NeoGenomics Laboratories

NeoGenomics Laboratories, founded in 2002, stands at the forefront of the Biotechnology, Health Care, and Pharmaceutical sectors. The company’s slogan, “One Lab. Vital Answers.,” encapsulates its mission of providing critical insights for personalized cancer treatment. Headquartered in the United States, NeoGenomics partners with physicians to enhance outcomes through tailored oncology solutions backed by an expert team.

The company’s dedication to precision oncology and its robust portfolio position it uniquely in the market. Its impressive track record includes a significant $200.00M Post IPO Equity investment round in May 2021, supported by high-profile investors such as Farallon Capital, Janus Henderson Investors, and RTW Investments. This financial backing underscores confidence in NeoGenomics' potential for growth and innovation within its industry.

Taxonomy: Cancer Testing, Oncology Portfolio, Personalized Treatment, Partnership Programs, Pathologists, Oncologists, Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology, Pathology, Next-Gen Sequencing (NGS)

Services & Products

Oncology solutions and testing
Biopharma services
Regulatory support
Oncology lab services
Genomic and biomarker insights

Target Customers

Oncologists Biopharma companies Healthcare organizations Cancer patients

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity $200.00M 3
Farallon Capital Janus Henderson Investors RTW Investments
01 May 2021
Post Ipo Convertible $125.40M - 01 Apr 2020
Post Ipo Equity $150.00M - 01 May 2019
Post Ipo Equity $125.00M - 01 Aug 2018
Post Ipo Debt $150.00M - 01 Dec 2016

View All 7 Funding Rounds

NeoGenomics Laboratories Alternatives & Competitors

View All Alternatives
NeoGenomics Laboratories vs
Cvergenx
Cvergenx United States

An innovative leader in cancer molecular diagnostics, delivering personalized radiation therapy to e...

Seed
2 employees
Biotechnology, Health Care
Compare NeoGenomics Laboratories vs Cvergenx
NeoGenomics Laboratories vs
ACT Genomics
ACT Genomics Taiwan

Make Personalized Medicine Accessible To All.

Series Unknown
121 employees
Biotechnology, Health Care
Compare NeoGenomics Laboratories vs ACT Genomics
NeoGenomics Laboratories vs
Amoy Diagnostics
Amoy Diagnostics China

Breaking Barriers to Precision Oncology

106 employees
Also compare with: NeoGenomics Laboratories vs IMD™ IMD™ View all alternatives

FAQ About NeoGenomics Laboratories

Answers are in our DNA™
NeoGenomics Laboratories was founded in 2002.
NeoGenomics Laboratories is headquartered in Fort Myers, United States.
NeoGenomics Laboratories operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
NeoGenomics Laboratories has approximately 1770 employees.
NeoGenomics Laboratories has completed 7 funding rounds, raising a total of $750.90M. The latest funding stage is IPO.
NeoGenomics Laboratories offers: Oncology solutions and testing, Biopharma services, Regulatory support, Oncology lab services, Genomic and biomarker insights.
Top alternatives and competitors to NeoGenomics Laboratories include Cvergenx, ACT Genomics, Amoy Diagnostics, IMD™, BioAlg Corp.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NeoGenomics Laboratories and Cvergenx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors NeoGenomics Laboratories and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy